Edrophonium and Atropine

(ed roe FOE nee um & A troe peen)

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Intravenous:

Enlon-Plus: Edrophonium chloride 10 mg/mL and atropine sulfate 0.14 mg/mL (15 mL [DSC]) [contains phenol, sodium sulfite]

Enlon-Plus: Edrophonium chloride 10 mg/mL and atropine sulfate 0.14 mg/mL (5 mL [DSC]) [contains sodium sulfite]

• Acetylcholinesterase Inhibitor
• Anticholinergic Agent
• Antidote

Edrophonium: Inhibits destruction of acetylcholine by acetylcholinesterase. This facilitates transmission of impulses across myoneural junction and results in increased cholinergic response.

Atropine: Minimizes or prevents the muscarinic cholinergic effects caused by edrophonium (eg, bradycardia, bronchoconstriction, increased secretions).

Excretion

Edrophonium: Primarily urine (67%)

There are no dosage adjustments provided in the manufacturer’s labeling.

Vital signs, ECG, and ventilatory support; neuromuscular function